Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Amy Oldendorp"'
Autor:
Rajbharan Yadav, Siddharth Sukumaran, Tanja S. Zabka, Jinze Li, Amy Oldendorp, Gary Morrow, Arthur Reyes, Melissa Cheu, Jessica Li, Jeffrey J. Wallin, Siao Tsai, Laura Sun, Peiyin Wang, Diego Ellerman, Christoph Spiess, Andy Polson, Eric G. Stefanich, Amrita V. Kamath, Meric A. Ovacik
Publikováno v:
Pharmaceutics, Vol 14, Iss 5, p 970 (2022)
The T cell-dependent bispecific (TDB) antibody, anti-CD79b/CD3, targets CD79b and CD3 cell-surface receptors expressed on B cells and T cells, respectively. Since the anti-CD79b arm of this TDB binds only to human CD79b, a surrogate TDB that binds to
Externí odkaz:
https://doaj.org/article/c576a9c94d774c0bbfd8b9f7d710cb3d
Autor:
Shraddha S, Sadekar, Mayumi, Bowen, Hao, Cai, Samira, Jamalian, Hanine, Rafidi, Whitney, Shatz-Binder, Julien, Lafrance-Vanasse, Pamela, Chan, William J, Meilandt, Amy, Oldendorp, Alavattam, Sreedhara, Ann, Daugherty, Susan, Crowell, Kristin R, Wildsmith, Jasvinder, Atwal, Reina N, Fuji, Joshua, Horvath
Publikováno v:
Clinical Pharmacology & Therapeutics. 111:826-834
Delivery of biologics via cerebrospinal fluid (CSF) has demonstrated potential to access the tissues of the central nervous system (CNS) by circumventing the blood-brain barrier and blood-CSF barrier. Developing an effective CSF drug delivery strateg
Autor:
Saroja Ramanujan, Arthur E. Reyes, Amy Oldendorp, Eric Stefanich, Melissa Cheu, Liping L. Sun, Gregory Z. Ferl
Publikováno v:
Clinical and Translational Science. 11:296-304
CD20 is a cell-surface receptor expressed by healthy and neoplastic B cells and is a well-established target for biologics used to treat B-cell malignancies. Pharmacokinetic (PK) and pharmacodynamic (PD) data for the anti-CD20/CD3 T-cell-dependent bi
Autor:
Jessica Couch, Sheila Ulufatu, C. Andrew Boswell, Danielle Mandikian, Gregory Z. Ferl, Saileta Prabhu, Isabel Figueroa, Amy Oldendorp, Sean B. Joseph, Noel Dybdal, Michelle G. Schweiger, Hanine Rafidi
Publikováno v:
The AAPS Journal. 20
We previously performed a comparative assessment of tissue-level vascular physiological parameters in mice and rats, two of the most commonly utilized species in translational drug development. The present work extends this effort to non-human primat
Autor:
Vanessa Shiu, Valerie Quarmby, John B. Lowe, Mauricio Maia, Amy Oldendorp, Jihong Yang, Mike Reich, Jacques Gaudreault, Henry B. Lowman, James Araujo, Samantha Lien
Publikováno v:
Experimental eye research. 85(4)
Neovascular age-related macular degeneration (AMD) is the leading cause of blindness in older adults in the Western world. Ranibizumab (Lucentis), a humanized antibody fragment directed against vascular endothelial growth factor (VEGF-A), was recentl
Autor:
Andrew Polson, Hong Wang, Eric Stefanich, Clarissa Johnson, L. Laura Sun, Xiaocheng Chen, Diego Ellerman, Allen J. Ebens, Arthur E. Reyes, Mary Mathieu, Bing Zheng, Peiyin Wang, Yvonne Chen, Mark S. Dennis, Amy Oldendorp
Publikováno v:
Blood. 124:4507-4507
T-cell recruiting bispecific antibodies and antibody fragments have been used to harness the cytotoxic potential of T cells for cancer treatment. As an example, encouraging clinical responses have been reported with the B cell targeting Blinatumomab,
Autor:
Nidhi Gupta, Dorothy French, Willy Solis, Elizabeth Luis, Susan D. Spencer, Glenn Pacheco, Suzie J. Scales, Katherine R. Kozak, Sarajane Ross, Reina N. Fuji, Elizabeth Drake, Mark S. Dennis, Josefa Chuh, Amy Oldendorp, Jay Tibbitts
Publikováno v:
Cancer Research. 74:4502-4502
Mesothelin (MSLN) is a cell surface glycoprotein widely expressed in several cancers with normal expression limited to the serosal mesothelia, features of an ideal target for antibody-based therapy. SS1P, a (dsFv)-PE38 immunotoxin to MSLN that kills